FDA Approves Priovant’s Oral Drug Litseraya for Dermatomyositis

The U.S. Food and Drug Administration (FDA) approved Priovant Therapeutics’ Litseraya to treat dermatomyositis. Litseraya is an oral TYK2 and JAK1 inhibitor discovered by Pfizer and licensed to Priovant. An estimated 34,000 patients in the United States have dermatomyositis. Priovant said its phase 3 trial showed that once-daily 30-mg dosing improved measures of muscle strength and skin health, while the rate of clinically meaningful improvement in itching was 75%, exceeding the 33% rate in the placebo group.